Enstilar® is more effective than Dovobet ointment* in achieving treatment success at week 41
Adapted from Koo J et al. J Dermatolog Treat 2016
Koo J et al., 2016:A multicentre, investigator-blinded Phase II study. Treatment success was defined as patients who achieved clear or almost clear skin with at least a two-step improvement according to PGA. 54.6% (n=77/141) of patients using Enstilar® achieved treatment success by week 4 vs 43.0% (n=58/135) using Dovobet ointment* (p=0.025).1
UK Enstilar® foam and Dovobet® ointment cost comparison:3
|Pack size||Treatment||Basic NHS Price|
|60 g||Enstilar® foam||£39.68|
|2 x 60 g|
Are you still using
Optimise your patient’s treatment
and advance them to Enstilar®
*Dovobet® ointment is not available in Ireland
LEO Pharma Product Licence Indications
Enstilar® is indicated for the topical treatment of psoriasis vulgaris in adults.1 Prescribing information can be found here
Dovobet® ointment is indicated for the topical treatment of stable plaque psoriasis vulgaris amenable to topical therapy in adults. Prescribing information can be found here
Dovobet® gel is indicated for scalp psoriasis in adults and the topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults.3. Prescribing information can be found here
- Koo J et al. J Dermatolog Treat2016; 27(2):120–127.
- King C et al.Poster 237 presented at the 5th Psoriasis International Network Annual Meeting, Paris, France, 5–7 July 2016.
- BNF formulary. https://www.medicinescomplete.com/mc/bnf/current/. Last accessed July 2019.